JP2014513046A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513046A5
JP2014513046A5 JP2013553647A JP2013553647A JP2014513046A5 JP 2014513046 A5 JP2014513046 A5 JP 2014513046A5 JP 2013553647 A JP2013553647 A JP 2013553647A JP 2013553647 A JP2013553647 A JP 2013553647A JP 2014513046 A5 JP2014513046 A5 JP 2014513046A5
Authority
JP
Japan
Prior art keywords
deuterium
alkyl
cycloalkyl
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013553647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024974 external-priority patent/WO2012112492A1/en
Publication of JP2014513046A publication Critical patent/JP2014513046A/ja
Publication of JP2014513046A5 publication Critical patent/JP2014513046A5/ja
Pending legal-status Critical Current

Links

JP2013553647A 2011-02-14 2012-02-14 4−ヒドロキシ酪酸の重水素化類似体 Pending JP2014513046A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161442451P 2011-02-14 2011-02-14
US61/442,451 2011-02-14
US201161484296P 2011-05-10 2011-05-10
US61/484,296 2011-05-10
PCT/US2012/024974 WO2012112492A1 (en) 2011-02-14 2012-02-14 4-hydroxybutyric acid deuterated analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083295A Division JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Publications (2)

Publication Number Publication Date
JP2014513046A JP2014513046A (ja) 2014-05-29
JP2014513046A5 true JP2014513046A5 (enExample) 2015-04-02

Family

ID=46672903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013553647A Pending JP2014513046A (ja) 2011-02-14 2012-02-14 4−ヒドロキシ酪酸の重水素化類似体
JP2017083295A Active JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083295A Active JP6692319B2 (ja) 2011-02-14 2017-04-20 4−ヒドロキシ酪酸の重水素化類似体

Country Status (10)

Country Link
US (5) US8759394B2 (enExample)
EP (1) EP2675771B1 (enExample)
JP (2) JP2014513046A (enExample)
KR (1) KR101976218B1 (enExample)
CN (1) CN103370289B (enExample)
BR (1) BR112013020620A2 (enExample)
ES (1) ES2804540T3 (enExample)
IL (1) IL227754B (enExample)
MX (1) MX355742B (enExample)
WO (1) WO2012112492A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CN108283000B (zh) * 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
HK1258020A1 (zh) * 2015-11-19 2019-11-01 株式会社大塚制药工场 3-羟基异戊酸的一价阳离子盐的晶体及该晶体的制造方法
RU2018145506A (ru) 2016-06-24 2020-07-27 Оцука Фармасьютикал Фэктори, Инк. Кристаллическая аминокислотная соль 3-гидроксиизовалериановой кислоты и способ ее получения
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
KR102510784B1 (ko) 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
JP2021519276A (ja) * 2018-03-23 2021-08-10 コンサート ファーマシューティカルズ インコーポレイテッド D−β−ヒドロキシ酪酸の重水素化類似体およびその使用
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程(武汉)有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
TW202139986A (zh) * 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR102982616B1 (ko) 2020-06-18 2026-06-26 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
CN113200853A (zh) * 2021-05-19 2021-08-03 宁波窦氏化学科技有限公司 一种制备丁二酸二醇酯的工艺方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
AU2024405251A1 (en) * 2023-12-22 2026-07-09 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
ZA814854B (en) * 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
US4548716A (en) * 1984-07-25 1985-10-22 Lucas Boeve Method of producing ultrapure, pyrogen-free water
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JP2727008B2 (ja) * 1989-02-01 1998-03-11 日本酸素株式会社 静菌化水の製造方法
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
AU783104B2 (en) * 1999-09-14 2005-09-22 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
WO2004006957A1 (en) 2002-07-15 2004-01-22 Alcon, Inc. Pharmaceutical compositions for otic use
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090082380A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched rosuvastatin
ES2589915T3 (es) * 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico

Similar Documents

Publication Publication Date Title
EP3043785B1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
IL310501A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2019520417A5 (enExample)
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2016534063A5 (enExample)
JP2016510317A5 (enExample)
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
HRP20171848T1 (hr) Upotreba malononitrilamida za neuropatsku bol
JP2014502641A5 (enExample)
AR082150A1 (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
JP2016513130A5 (enExample)
BR112014004963A2 (pt) sal de colina do composto anti-inflamatório ciclobutanodiona substituído
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
JP2015535247A5 (enExample)
JP2022510587A5 (enExample)
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
JP2015509075A5 (enExample)
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
JP2011529069A5 (enExample)
JP2014515407A5 (enExample)
WO2010066931A4 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2022536160A5 (enExample)
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof